Researchers hail success of scheme to protect capercaillie chicks from predators
With just over 500 of the ground-nesting birds left in the wild, the capercaillie, a large woodland grouse, is in danger of extinction in the UK.
One contributor to the birds' decline is the eating of eggs and chicks by predators – including the pine marten, another protected species.
In an effort to protect capercaillie broods while not harming the predators themselves, researchers at the University of St Andrews used a 'diversionary feeding' scheme to give predators an easy alternative food to capercaillie nests.
The study, which was carried out in and around the Cairngorms National Park over three years, saw researchers leave out deer carrion for predators at the 'critical' eight-week period when capercaillie are nesting and hatching.
The result, as captured on camera traps, was a doubling of the number of broods in areas where alternative food was available, with 85% of monitored capercaillie having chicks in these areas, compared with just 37% in 'unfed' sites.
The study team said this equated to an increase in the number of chicks per hen from 0.82 chicks per hen without feeding to 1.90 with feeding – an increase in capercaillie productivity of 130%.
Dr Jack Bamber, from the University of Aberdeen, said 'This study provides compelling, robust, landscape-scale evidence that diversionary feeding can reduce the impact of recovering predators, without killing them, aligning with shifting ethical and ecological goals for conservation management in the UK.
'The combination of rigorous experimentation and innovative monitoring indicates that this method is worth exploration for other species vulnerable to predation, with land managers concerned with other rare prey, and land managers aiming to help capercaillie elsewhere in Europe already considering this tool as an option for them to trial and apply in future.'
The team said the study confirmed that the boost in chicks per hen was directly linked to a higher chance that a hen had a brood at all, indicating, they said, that diversionary feeding reduces catastrophic brood failure often caused by nests being raided by predators.
Diversionary feeding is now endorsed in the Cairngorms Capercaillie Emergency Action Plan, with 18 independent land holdings using the method to help the endangered bird in 2025.
Dr Chris Sutherland from the Centre for Research into Ecology and Environmental Modelling at the University of St Andrews said: 'This project is an excellent example of how the impact of research can be maximised when it is co-designed in close collaboration with the wildlife managers and policy makers.
'Doing so enabled us to deliver timely decision-ready evidence underpinned by scientific and statistical rigour'.
The findings build on earlier results from an artificial-nest study published in 2024 that found a 50% reduction in pine marten predation, as a result of diversionary feeding, led to a nearly 83% increase in artificial nest survival.
The project was a partnership between the University of St Andrews, the University of Aberdeen, Forestry and Land Scotland, RSPB Scotland, NatureScot and Wildland Ltd working under the umbrella of the Cairngorms Connect Predator Project.
It was funded by the Scottish Universities Partnership for Environmental Research Doctoral Training Partnership, and the findings were published in the journal Proceedings of the Royal Society B.
Get all the latest news from around the country Follow STV News
Scan the QR code on your mobile device for all the latest news from around the country
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medical News Today
2 days ago
- Medical News Today
GLP-1 drugs for diabetes and weight loss may also help control asthma
Researchers based in the United Kingdom recently examined how GLP-1 agonist drugs impact asthma in people with taking GLP-1 medications had better-controlled asthma overall, though there was no difference in lung function compared to those not taking study suggests that GLP-1 drugs may have anti-inflammatory effects that benefit the lungs. Healthcare providers often prescribe GLP-1 drugs such as semaglutide (Ozempic and Wegovy) or liraglutide (Victoza and Saxenda) for type 2 diabetes control and weight loss. As these medications increase in popularity, researchers are looking into other ways these drugs can be useful. Recent research shows that GLP-1 medications may reduce obesity-related cancer risk and may lower dementia from the University of Aberdeen and the Observational and Pragmatic Research Institute in the United Kingdom recently examined how these medications impact asthma control in people with obesity. They found that people taking GLP-1 medications had better-controlled asthma findings are published in the journal Advances in how GLP-1 drugs impact asthmaGLP-1 receptor agonists are a type of medication that mimic the hormone glucagon-like peptide-1 to help regulate blood sugar, increase insulin secretion, reduce gastric emptying, and increase appetite satiety. These medications treat type 2 diabetes and assist in weight loss in people who are either overweight or have obesity. GLP-1s have shown anti-inflammatory effects, and since an inflammatory response triggers asthma, researchers in the current study wanted to see what effects these medications have on people with obesity and asthma. The study examined around 60,000 people, including more than 10,000 people with both obesity and asthma taking GLP-1 drugs and around 50,000 matched controls. The researchers used data from the Optimum Patient Care Research order to qualify for inclusion in the study, the participants needed to have had an asthma consultation in the 12 months before starting the GLP-1 medication. They also had to be at least 18 years old and have a body mass index (BMI) of more than 30, which indicates obesity. Each participant in the GLP-1 group was matched 5:1 with participants who had similar characteristics but had not taken GLP-1 medications. People on GLP-1 drugs had marked asthma improvementThe researchers used an average of 3 years of follow-up data to determine how well people with asthma who were on GLP-1 medications did compared to people in the matched group. They used the participants' baseline risk domain asthma control (RDAC) and overall asthma control (OAC) scores and compared these to scores taken during follow-up. While the GLP-1 group had a higher average BMI and worse asthma control before starting the GLP-1 drugs, they had 'significant' improvements in their asthma scores after being on the GLP-1 medication for a GLP-1 group did not differ much from the matched group at the end of the study in terms of lung function. The authors point to missing data due to the COVID-19 pandemic on this measurement.'Obese asthmatics are unique in that they are often steroid-resistant, and it is possible that mechanistic differences in obese asthmatics and weight loss with GLP1 may have pleomorphic effects on inflammation beyond just weight loss,' the study authors the study findings demonstrate that GLP-1 medications have the potential to positively impact asthma in people with obesity. Further research is needed, though, especially to determine whether these medications can one day be used to treat respiratory issues. Experts disagree on whether GLP-1 contributes to asthma controlJimmy Johannes, MD, pulmonologist and critical care medicine specialist at MemorialCare Long Beach Medical Center, spoke with Medical News Today about the study.'This study further supports the link between weight loss, in this case with GLP-1 drugs, and improved asthma control,' said Johannes. 'It also raises the possibility that GLP-1 drugs may be helpful for the treatment of asthma.'Johannes discussed the mechanism by which the GLP-1 drugs improved asthma and noted that there are GLP-1 receptors in the lungs. 'GLP-1 receptor agonists may be able to directly reduce the inflammation and airway hyperresponsiveness that contribute to asthma,' Johannes explained. Thomas Kilkenny, DO, director of the Institute of Sleep Medicine, Pulmonary & Critical Care at Northwell's Staten Island University Hospital, also spoke with MNT about the did not think the study adequately demonstrated that GLP-1 medications were responsible for the improved asthma control and suggested that the improvements could be related to weight loss. Is it GLP-1s or weight loss?'It has been shown multiple times in the past, and various studies show that weight loss alone improves asthma control. This study did not comment on whether the GLP-1 medication had a direct effect on the physiology of asthma control.'— Thomas Kilkenny, DOKilkenny explained that weight loss alone improves asthma control for several reasons, including 'a decrease in the low-grade inflammation that is associated with obesity.'
BBC News
3 days ago
- BBC News
University of Aberdeen study says weight loss jabs may aid asthma
Weight loss injections could help to reduce asthma symptoms in obese people, according to researchers at the University of study by an international team of scientists found as well as the weight loss aspect, the drugs - called GLP-1s - also led to improved control of the respiratory analysed the medical records of more than 60,000 is hoped the injections could be used as a potential treatment in the future, as obese people are often resistant to steroids which are used to help control asthma. GLP-1s mimic a naturally-occurring hormone and help regulate blood sugar, insulin and control David Price from the University of Aberdeen said: "People with obesity and asthma are unique in that they are often resistant to steroid treatments."We know that GLP-1s work on inflammatory responses in the airways in a different way to traditionally used steroids."We found compelling evidence that GLP-1s, as well as increasing weight loss, also improved asthma symptoms."He said their findings suggested the drugs might have beneficial effects on asthma control for people with obesity and that should be "explored further". 'Promising alternative' Dr Erika Kennington, head of research and innovation at Asthma + Lung UK, said research had previously shown than people living with obesity who lost weight saw "improved control" of their said it was "encouraging" the study had shown that was still the case when using weight loss drugs."Although exercise can help people lose weight, for some people it can cause anxiety about becoming breathless or having an asthma attack," she said."So people are stuck in a vicious cycle of not being able to lose weight and their asthma worsening."Therefore, where exercise hasn't worked for someone these drugs that support weight loss could offer a promising alternative."However, she said it was "too early to say" whether the drugs would be effective for people with asthma more widely."More research is needed to understand how these drugs actually improve asthma control," she added."Funding for lung health research is on life support and urgent action is needed to increase investment."
Daily Mirror
3 days ago
- Daily Mirror
Jabs like Mounjaro 'could help manage asthma for obese people'
Researchers said the drugs should be explored as a potential treatment for obese people with the respiratory condition, who are "often resistant" to steroids Injections used by those trying to lose weight could potentially alleviate asthma symptoms in obese people, a recent study suggests. The research indicates that these drugs, also known as glucagon-like peptide1 receptor-agonists (GLP1-RAs), should be considered as a potential treatment for obese people suffering from the respiratory condition, who are "often resistant" to steroids. These injections - originally developed as a treatment for type 2 diabetes - function by imitating the hormone GLP-1, which helps regulate blood sugar and insulin levels. Several variations of the drug are recommended by the NHS to combat obesity, including semaglutide, also known as Wegovy, and tirzepatide, or Mounjaro. Previous research has suggested that these drugs may significantly reduce the risk of diseases such as dementia and stroke. An international team of experts is currently investigating their potential impact on obese people with asthma, reports Bristol Live. Professor David Price, chair in primary care respiratory medicine at the University of Aberdeen, stated: "People with obesity and asthma are unique in that they are often resistant to steroid treatments. We know that GLP1s work on inflammatory responses in the airways in a different way to traditionally used steroids." In the study, published in Advances in Therapy, researchers analysed the records of 10,111 people on GLP1-RAs, and 50,555 people who were not on the drugs. Following a period of observation, the team discovered that those taking the injections lost more weight and had improved control over their asthma. Researchers have suggested that medical professionals "should pay attention to the relationship between GLP-1 RA and the risk of respiratory diseases". Prof Price stated: "We found compelling evidence that GLP1s, as well as increasing weight loss, also improved asthma symptoms. "In addition, it is important to note that the benefits to asthma symptoms occurred despite fairly modest weight loss of around 0.9kg over the course of the year. Our findings suggest that GLP1s may have beneficial effects on asthma control for people with obesity and this should be explored further." Prof Alan Kaplan, chairperson of the Family Physician Airways Group of Canada and the Observational and Pragmatic Research Institute, commented: "Our findings suggest that GLP1-RAs have benefits on asthma control in people with obesity, and this information should contribute to the discussions around the decision to use these drugs." Dr Erika Kennington, head of research and innovation at Asthma and Lung UK, said: "Research has previously shown that people living with obesity who lose weight see improved control of their asthma, so it's encouraging to see this study show this is still the case when the weight loss is driven by drugs, like the new class of weight loss drugs. "Although exercise can help people lose weight, for some people it can cause anxiety about becoming breathless or having an asthma attack, so people are stuck in a vicious cycle of not being able to lose weight and their asthma worsening. Therefore, where exercise hasn't worked for someone these drugs that support weight loss could offer a promising alternative. "It's too early to say whether these drugs would be effective for people with asthma more widely. More research is needed to understand how these drugs actually improve asthma control. Funding for lung health research is on life support and urgent action is needed to increase investment."
